|
15 Dec 2022 |
Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus
|
|
15 Dec 2022 |
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
|
|
15 Dec 2022 |
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
|
|
15 Dec 2022 |
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
|
|
15 Dec 2022 |
Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company’s Second Therapeutic Candidate for Sensorineural Hearing Loss
|
|
15 Dec 2022 |
Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting
|
|
15 Dec 2022 |
AnHeart Therapeutics Receives FDA Clearance of IND Application to Initiate Global Phase 2 Study of Safusidenib in Glioma
|
|
14 Dec 2022 |
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
|
|
14 Dec 2022 |
Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)
|
|
14 Dec 2022 |
BeiGene’s BRUKINSA® (zanubrutinib) Demonstrated Superior Progression-Free Survival Over IMBRUVICA® (ibrutinib) in Chronic Lymphocytic Leukemia in Late-Breaker at ASH
|
|
13 Dec 2022 |
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
|
|
13 Dec 2022 |
Preclinical Data from Kymera Therapeutics’ Collaborations Demonstrate Therapeutic Potential of STAT3 Degraders in CTCL and IRAKIMiD Combination with BCL-2 Inhibitor in MYD88-Mutant DLBCL at the American Society of Hematology Annual Meeting
|
|
13 Dec 2022 |
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
|
|
13 Dec 2022 |
Mirum Pharmaceuticals’ LIVMARLI (maralixibat) Approved by the European Commission for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome Two Months and Older
|
|
13 Dec 2022 |
Loxo@Lilly Presents Updated Pirtobrutinib Data from the Phase 1/2 BRUIN Clinical Trial at the 2022 American Society of Hematology Annual Meeting
|
|
11 Dec 2022 |
Sumitomo Pharma Oncology Presents Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at American Society of Hematology 2022 Annual Meeting & Exposition
|
|
10 Dec 2022 |
Orum Therapeutics Presents Positive Preclinical Data of ORM-6151, a First-in-Class, CD33-GSPT1 Dual-Precision Targeted Protein Degrader for AML, at ASH 2022
|
|
09 Dec 2022 |
First-in-Class Investigational SX-682 Demonstrates Single-Agent Efficacy in Patients with Hypomethylating Agent Failure Myelodysplastic Syndromes
|
|
09 Dec 2022 |
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
|
|
08 Dec 2022 |
iOnctura initiates Phase Ib pancreatic cancer trial of next-generation autotaxin inhibitor IOA-289
|
|
08 Dec 2022 |
Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022
|
|
08 Dec 2022 |
Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
|
|
08 Dec 2022 |
Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
|
|
08 Dec 2022 |
Design Therapeutics Reports Positive Data from Single-Ascending Dose Trial of DT-216 for the Treatment of Friedreich Ataxia and Portfolio Progress
|
|
08 Dec 2022 |
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
|
